Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
July 2012, Vol 3, No 5
July 2012, Vol 3, No 5
High Response Rate with Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
In the Literature
July 2012, Vol 3, No 5
Newly reported results of a phase 2 clinical trial have shown that treatment with the antibody-drug conjugate brentuximab vedotin achieves high response rates in patients with relapsed or refractory HL whose disease has progressed even after receiving autologous stem-cell transplant (auto-SCT) salvage therapy (Younes A, et al.
J Clin Oncol
. 2012;30:2183-2189).
Read Article
The Affordable Care Act: The Day of Reckoning Arrives
By
Ross D. Margulies, JD, MPH
;
Jayson Slotnik, JD, MPH
Health Policy
,
Policies & Guidelines
July 2012, Vol 3, No 5
Over the past 2 years, we have written about the impact of accountable care organizations, value-based purchasing, health insurance exchanges, and other programs relevant to the oncology community. These initiatives were all born out of the Affordable Care Act (ACA), which, on June 28, 2012, had its major day of reckoning.
Read Article
Defining the Roles of Patient Navigation Can Remove Barriers to Quality Care
Patient Navigation
July 2012, Vol 3, No 5
Houston, TX—Patient navigation assures timely access to care for many patients, especially the medically underserved population, and it will soon become mandated for institutions accredited by the Commission on Cancer, reported Mandi Pratt-Chapman, MA, Associate Director of the Community Programs, Codirector of the Center for the Advancement of Cancer Survivorship, Navigation and Policy, George Washington Cancer Institute, Washington, DC, at the Second Annual Conference of the Association for Value-Based Cancer Care.
Read Article
New Androgen Receptor–Signaling Inhibitor Extends Survival, Improves QOL in Advanced Prostate Cancer
By
Mark Knight
ASCO Annual Meeting
,
ASCO
July 2012, Vol 3, No 5
Chicago, IL—The novel androgen receptor–signaling inhibitor enzalutamide, also known as MDV3100, significantly prolonged overall survival (OS), slowed disease progression, and improved quality-of-life (QOL) measures in men with castration-resistant prostate cancer after docetaxel failure, according to results from a large phase 3 clinical trial.
Read Article
Can Drug Cost Drive Oral Medication Adherence Up?
By
Audrey Andrews
ASCO Annual Meeting
,
ASCO
July 2012, Vol 3, No 5
Chicago, IL—Canadian researchers reported a finding at the 2012 American Society of Clinical Oncol ogy meeting that runs contrary to what other researchers have observed in the majority of studies.
Read Article
Page 4 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma